Edwards Lifesciences management check
EW · Health Care · Health Care Equipment · CEO Bernard J Zovighian
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
1728thDetail
$100 invested at the start of fiscal 2021 grew to $93, against $127 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8863rdDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.77 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.6% of net income
What does the CEO cost owners?
$17.5m pay · $1.1bn net income, FY2025
3234thDetail
$17.5m of reported pay in fiscal 2025, against $1.1bn of net income.
- FlagCEO stake ≈ 0.7 years of pay
Do they own the stock?
121,945 shares ≈ $12.5m
6 mo: ▲ $0 bought · ▼ $14.4m sold
88thDetail
The CEO holds 121,945 shares, directly or through trusts (unvested awards not counted): about 0.7 years of pay. 7 insiders sold $14.4m in the last six months and none bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.0% a year; flagged above +2%
Stock pay 2.6% of revenue
7467thDetail
Diluted shares changed -2.0% a year over the last three fiscal years. Stock-based pay was 2.6% of revenue in the latest year.
- Good9 leadership filings in 3 years
Is leadership stable?
9 filings under 8-K 5.02 in 3 years
8056thDetail
9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 26, 2026.
Pay tied most to •Underlying Revenue Growth
Other key measuresRelative TSR•Adjusted Earnings Per Share•KOD Measurement
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | — | $17.5m | $21.3m | $4.7m | $93 | $127 | $1.1bn |
| 2024 | — | $14.6m | $9.2m | $4.4m | $81 | $117 | $1.4bn |
| 2023 | — | $12.9m | $11.0m | $5.0m | $84 | $106 | $1.4bn |
| 2022 | — | $14.0m | −$10.5m | $4.2m | $82 | $97 | $1.5bn |
| 2021 | — | $13.6m | $31.5m | $3.5m | $142 | $119 | $1.5bn |
Insiders and the CEO's stakeSelling
- Shares held
- 121,945
- At that filing's price
- ≈ $12.5m
- Latest Form 4
- Nov 9, 2026
7 insiders sold $14.4m in the last six months and none bought. 10 of 21 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldDonald E Jr BoboCVP,Strategy/Corp Development$7.0mNov 9, 2026
- SoldDaveen ChopraCVP, TMTT, Surgical & IHFM$3.0mAug 26, 2026
- SoldBernard J ZovighianCEO$2.7mNov 9, 2026
- SoldWayne MarkowitzCVP, JAPAC$945kAug 26, 2026
Leadership and governance on file
All 11 filings
- Aug 28, 2026Leadership change8-K 5.02
- May 8, 2026Leadership change8-K 5.02
- May 4, 2026Leadership change8-K 5.02
- Oct 30, 2025Leadership change8-K 5.02
- Jul 25, 2025Leadership change8-K 5.02
- May 8, 2025Leadership change8-K 5.02
- Jul 10, 2024Leadership change8-K 5.02
- Jun 17, 2024Leadership change8-K 5.02
- Mar 26, 2024Leadership change8-K 5.02
- May 15, 2023Leadership change8-K 5.02
- Dec 8, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 8, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $5.2bn returned to owners in buybacks and dividends, 53% of net income, and $695.9m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.2bn | $4.5bn | $5.0bn | $5.4bn | $6.1bn |
| Net income | $1.5bn | $1.5bn | $1.4bn | $4.2bn | $1.1bn |
| Stock-based pay | $109.3m | $126.8m | $139.4m | $162.3m | $158.1m |
| Buybacks | $512.8m | $1.7bn | $879.6m | $1.2bn | $893.4m |
| Dividends | — | — | — | — | — |
| Diluted shares | 631m | 624m | 609m | 599m | 586m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.